Article

Verdict's In: Percutaneous Balloon Mitral Valvuloplasty Works Well

Author(s):

Percutaneous balloon mitral valvulopasty (PMV) has now been around long enough for long term outcomes to be assessed. The verdict is positive.

Percutaneous balloon mitral valvulopasty (PMV) has now been around long enough for long-term outcomes to be assessed.

Reporting at the ESC Congress 2016 Ines Rodriges of Hospital de Santa Marta, Lisbon, Portugal, and colleagues reviews outcomes of patients who had the procedure to correct rheumatic mitral stenosis.

Of 213 consecutive patients who had PMV in a single center, from 1991 to 2 014, 89% had a successful PMV. During a mean followup period of 11.2 years, only 25.15% of patients had a major cardiac event. Of those 6.6% were deaths, 6.6% repeat PVM, and 21% mitral surgery.

Cumulative event-free survival at 20 years was 54.7%.

"Up to 20 years after successful PMV, a sizeable proportion of patients are event-free, which confirms the late efficacy of PMV," the team concluded.

"In our cohort, echocardiographic score before PMV was the only independent predictor of event-free survival," they added.

Previous studies have shown low technical failure and major complications with PMV, they noted.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.